Falling Walls Venture is a global platform for the most promising science start-ups nominated by academic institutions from across the world. The format provides a stage for pioneering founders who have successfully turned science into business, proving how entrepreneurial solutions can help solve today’s most pressing challenges. Every year, emerging companies compete across various industry clusters. The winner of the competition is awarded the title “Science Start-Up Breakthrough of the Year”.
Throughout the year, universities and research institutions from all over the world are called upon to nominate their most innovative science start-up for the competition. The most promising young companies are invited to pitch on the Falling Walls Venture stage. Additionally, they gain access to exclusive networking events and the Falling Walls Community.
A high-calibre jury of international experts, investors, and corporate innovation leaders, chaired by Stefan von Holtzbrinck, CEO of Holtzbrinck Publishing Group, will select one of the winners as the “Science Start-Up Breakthrough of the Year”. The grand winner will be made public on 9 November 2021, the anniversary of the historic fall of the Berlin Wall, and the people and institutions who made them possible will be honoured in a live digital session with distinguished global leaders, high-ranking industry representatives as well as a global audience following the event via livestream.
Falling Walls Venture is generously supported by the Berlin Senate and by our global partner Boehringer Ingelheim, as well as by numerous international partner universities and research institutions.
“In Falling Walls Venture, startups find an enthusiastic and supportive community from all over the world!”
Christian Elias Schneider – Universität Basel
“One of the most anticipated events for top start-ups.“
Carsten Mahrenholz – Coldplasmatech
“The level of energy you get from Falling Walls is just incredible.”
Alison Mitchell – Springer Nature
“We met the Falling Walls Venture winner, T3 Pharmaceuticals, at the event and were immediately convinced by the scientific concept – so we participated in the second round of financing.”
Frank Kalkbrenner – Boehringer Ingelheim Venture Fund